Jessica R Kirshner
Overview
Explore the profile of Jessica R Kirshner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tavare R, Danton M, Giurleo J, Makonnen S, Hickey C, Arnold T, et al.
Cancer Immunol Res
. 2022 Jul;
10(10):1190-1209.
PMID: 35895745
Assessment of immune-cell subsets within the tumor immune microenvironment is a powerful approach to better understand cancer immunotherapy responses. However, the use of biopsies to assess the tumor immune microenvironment...
2.
Zhu M, Olson K, Kirshner J, Toroghi M, Yan H, Haber L, et al.
Clin Transl Sci
. 2022 Jan;
15(4):954-966.
PMID: 34997701
Odronextamab is a fully-human IgG4-based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T-cell-mediated cytotoxicity independent of T-cell-receptor recognition. Adequate safety, tolerability,...
3.
Haber L, Olson K, Kelly M, Crawford A, DiLillo D, Tavare R, et al.
Sci Rep
. 2021 Jul;
11(1):14397.
PMID: 34257348
T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific antigens (TSA), inducing...
4.
DiLillo D, Olson K, Mohrs K, Meagher T, Bray K, Sineshchekova O, et al.
Blood Adv
. 2021 Mar;
5(5):1291-1304.
PMID: 33651100
CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully...
5.
Kelly M, Makonnen S, Hickey C, Arnold T, Giurleo J, Tavare R, et al.
J Immunother Cancer
. 2021 Jan;
9(1).
PMID: 33483343
Background: Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodies including cemiplimab have generated profound clinical activity across diverse cancer types. Tumorous PD-L1 expression, as assessed by immunohistochemistry (IHC),...
6.
Nittoli T, Delfino F, Kelly M, Carosso S, Markotan T, Kunz A, et al.
Bioorg Med Chem
. 2020 Oct;
28(23):115785.
PMID: 33099182
ADCs based on the natural product maytansine have been successfully employed clinically. In a previous report, ADCs based on hydrophilic non-cell permeable maytansinoids was presented. The authors in this report...
7.
Chiu D, Tavare R, Haber L, Aina O, Vazzana K, Ram P, et al.
Cancer Immunol Res
. 2020 Mar;
8(5):596-608.
PMID: 32184296
Patients with hematologic cancers have improved outcomes after treatment with bispecific antibodies that bind to CD3 on T cells and that redirect T cells toward cancer cells. However, clinical benefit...
8.
Skokos D, Waite J, Haber L, Crawford A, Hermann A, Ullman E, et al.
Sci Transl Med
. 2020 Jan;
12(525).
PMID: 31915305
T cell activation is initiated upon binding of the T cell receptor (TCR)/CD3 complex to peptide-major histocompatibility complexes ("signal 1"); activation is enhanced by engagement of a second "costimulatory" receptor,...
9.
Crawford A, Haber L, Kelly M, Vazzana K, Canova L, Ram P, et al.
Sci Transl Med
. 2019 Jun;
11(497).
PMID: 31217340
Advanced ovarian cancer is frequently treated with combination chemotherapy, but high recurrence rates show the need for therapies that can produce durable responses and extend overall survival. Bispecific antibodies that...
10.
Cheal S, Ruan S, Veach D, Longo V, Punzalan B, Wu J, et al.
Mol Pharm
. 2018 Apr;
15(6):2133-2141.
PMID: 29684277
Antibodies labeled with positron-emitting isotopes have been used for tumor detection, predicting which patients may respond to tumor antigen-directed therapy, and assessing pharmacodynamic effects of drug interventions. Prolactin receptor (PRLR)...